Concepedia

Author

Daniel Ford

Institute of Cancer Research

Also Known As

D FORD, D. Ford, D. R. Ford, D.R. Ford, Daniel Ford, Daniel R. Ford, Debbie Devonport, Dianne Ford, Ford, Daniel Resau (author)

67

Publications

4.6K

Citations

25

H-Index

50

Concepts

All Affiliations

Institute of Cancer ResearchQueen Elizabeth Hospital BirminghamClatterbridge Cancer Centre NHS Foundation TrustRoyal Marsden NHS Foundation TrustCardiff University
DF

About

Daniel Ford is an author at Institute of Cancer Research specializing in medicine, oncology, and surgical oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

11

11

2.3K

2

Health Sciences

3

3

87

3

Biology

2

2

132

4

Natural Sciences

1

1

89

5

Anatomy

1

1

21

Daniel Ford

×

27

Publications

4.4K

Citations

24

H-Index

YearCitations

Risks of cancer in BRCA1-mutation carriers

Daniel Ford

The Lancet

1994

1.9K

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial

Douglas Brand, Alison Tree, Peter Ostler,

The Lancet Oncology

2019

519

Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m<sup>2</sup>) and the Currently Approved Dose (25 mg/m<sup>2</sup>) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer—PROSELICA

Mario A. Eisenberger, Anne-Claire Hardy-Bessard, Choung‐Soo Kim,

Journal of Clinical Oncology

2017

282

Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial

Alison Tree, Peter Ostler, H. van der Voet,

The Lancet Oncology

2022

280

Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol

Matthew R. Sydes, Melissa Spears, Malcolm D. Mason,

Annals of Oncology

2018

240

Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer

Nicholas van As, Clare Griffin, Alison Tree,

New England Journal of Medicine

2024

172

Transcriptional profiling of MnSOD-mediated lifespan extension in Drosophilareveals a species-general network of aging and metabolic genes

Christina Curtis, Gary N. Landis, Donna G. Folk,

Genome biology

2007

143

Radiotherapy to the prostate for men with metastatic prostate cancer in the UK and Switzerland: Long-term results from the STAMPEDE randomised controlled trial

Chris Parker, Nicholas D. James, Chris Brawley,

PLoS Medicine

2022

112

Alteration of Drosophila life span using conditional, tissue-specific expression of transgenes triggered by doxycyline or RU486/Mifepristone

Daniel Ford, Nicholas Hoe, Gary N. Landis,

Experimental Gerontology

2007

89

Abiraterone acetate plus prednisolone with or without enzalutamide for patients with metastatic prostate cancer starting androgen deprivation therapy: final results from two randomised phase 3 trials of the STAMPEDE platform protocol

Gerhardt Attard, Laura Murphy, Noel W. Clarke,

The Lancet Oncology

2023

85

Page 1